CY1110037T1 - Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες - Google Patents
Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερεςInfo
- Publication number
- CY1110037T1 CY1110037T1 CY20101100427T CY101100427T CY1110037T1 CY 1110037 T1 CY1110037 T1 CY 1110037T1 CY 20101100427 T CY20101100427 T CY 20101100427T CY 101100427 T CY101100427 T CY 101100427T CY 1110037 T1 CY1110037 T1 CY 1110037T1
- Authority
- CY
- Cyprus
- Prior art keywords
- packages
- formulations
- pyridyl ethers
- benzimidazolyl pyridyl
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Παρέχονται σκευάσματα, που περιλαμβάνουν: μια ένωση του Χημικού τύπου (I), ένα φαρμακευτικώς αποδεκτό άλας αυτών, ή ένα μείγμα οποιωνδήποτε δυο ή περισσότερων εξ αυτών, και ένα συστατικό επιλεγμένο από έναν υδρόφιλο διαλύτη, έναν λιπόφιλο διαλύτη, έναν γαλακτωματοποιητή, ή ένα μείγμα οποιωνδήποτε δυο ή περισσότερων εξ αυτών, όπου η ένωση του Χημικού τύπου (I) είναι, σε μερικές εκδοχές, τα σκευάσματα είναι υγρά. Σε άλλες εκδοχές, τα σκευάσματα είναι στερεά. Επίσης παρέχονται μέθοδοι για την παρασκευή τέτοιων σκευασμάτων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83271506P | 2006-07-21 | 2006-07-21 | |
EP07810647A EP2046292B1 (en) | 2006-07-21 | 2007-07-20 | Formulations for benzimidazolyl pyridyl ethers |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110037T1 true CY1110037T1 (el) | 2015-01-14 |
Family
ID=38819293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100427T CY1110037T1 (el) | 2006-07-21 | 2010-05-14 | Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες |
Country Status (20)
Country | Link |
---|---|
US (1) | US8455662B2 (el) |
EP (1) | EP2046292B1 (el) |
JP (1) | JP2009544617A (el) |
KR (1) | KR20090033904A (el) |
CN (1) | CN101516335B (el) |
AT (1) | ATE459338T1 (el) |
AU (1) | AU2007275634B2 (el) |
BR (1) | BRPI0715423A2 (el) |
CA (1) | CA2657346A1 (el) |
CY (1) | CY1110037T1 (el) |
DE (1) | DE602007005139D1 (el) |
DK (1) | DK2046292T3 (el) |
ES (1) | ES2340631T3 (el) |
HR (1) | HRP20100293T1 (el) |
MX (1) | MX2009000770A (el) |
PL (1) | PL2046292T3 (el) |
PT (1) | PT2046292E (el) |
RU (2) | RU2452469C2 (el) |
SI (1) | SI2046292T1 (el) |
WO (1) | WO2008011154A2 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
PE20130814A1 (es) * | 2006-08-30 | 2013-08-08 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
RU2483064C2 (ru) * | 2007-03-02 | 2013-05-27 | Новартис Аг | Твердые формы ингибитора raf-киназы |
WO2010040055A2 (en) * | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
EP2588081A4 (en) * | 2010-06-29 | 2014-12-10 | Verastem Inc | ORAL FORMULATION OF CHINESE INHIBITORS |
JP5923499B2 (ja) | 2010-06-30 | 2016-05-24 | ベラステム インコーポレイテッド | キナーゼインヒビターの合成および使用 |
CN102336740B (zh) * | 2010-07-27 | 2013-07-24 | 中国科学院上海药物研究所 | 一类咪唑类化合物及其用途 |
CN103301067B (zh) * | 2012-03-15 | 2018-09-11 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
US9724354B2 (en) | 2013-03-22 | 2017-08-08 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase |
US10561627B2 (en) * | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
SG10202103552XA (en) | 2015-03-09 | 2021-05-28 | Intekrin Therapeutics Inc | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
EP3606527A1 (en) | 2017-04-03 | 2020-02-12 | Coherus Biosciences, Inc. | Ppar-gamma agonist for treatment of progressive supranuclear palsy |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
KR0179401B1 (ko) * | 1994-02-28 | 1999-03-20 | 송택선 | 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체 |
US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
IL127210A0 (en) | 1996-05-23 | 1999-09-22 | Applied Research Systems | Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
ME00275B (me) | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
US6391683B1 (en) * | 2000-06-21 | 2002-05-21 | Siliconware Precision Industries Co., Ltd. | Flip-chip semiconductor package structure and process for fabricating the same |
US6756410B2 (en) | 2000-08-30 | 2004-06-29 | Kamal D. Mehta | Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2 |
AU2001262945B2 (en) * | 2000-09-20 | 2006-02-02 | Skyepharma Canada Inc. | Spray drying process and compositions of fenofibrate |
US20040131670A1 (en) * | 2001-04-17 | 2004-07-08 | Ping Gao | Pellicle-resistant gelatin capsule |
US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
MXPA04009541A (es) | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
US20050082192A1 (en) * | 2002-06-17 | 2005-04-21 | Eric Smarr | End cap support for jumbo rolls of material |
WO2005112932A2 (en) * | 2004-05-07 | 2005-12-01 | Exelixis, Inc. | Raf modulators and methods of use |
PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
US20100231394A1 (en) * | 2009-03-11 | 2010-09-16 | Bobby Eugene Finchum | Carbon monoxide detection and dissipation apparatus |
-
2007
- 2007-07-20 JP JP2009520854A patent/JP2009544617A/ja not_active Ceased
- 2007-07-20 SI SI200730219T patent/SI2046292T1/sl unknown
- 2007-07-20 PL PL07810647T patent/PL2046292T3/pl unknown
- 2007-07-20 KR KR1020097003547A patent/KR20090033904A/ko not_active Application Discontinuation
- 2007-07-20 CA CA002657346A patent/CA2657346A1/en not_active Abandoned
- 2007-07-20 DK DK07810647.3T patent/DK2046292T3/da active
- 2007-07-20 WO PCT/US2007/016469 patent/WO2008011154A2/en active Application Filing
- 2007-07-20 PT PT07810647T patent/PT2046292E/pt unknown
- 2007-07-20 RU RU2009105819/15A patent/RU2452469C2/ru not_active IP Right Cessation
- 2007-07-20 AT AT07810647T patent/ATE459338T1/de active
- 2007-07-20 DE DE602007005139T patent/DE602007005139D1/de active Active
- 2007-07-20 EP EP07810647A patent/EP2046292B1/en active Active
- 2007-07-20 AU AU2007275634A patent/AU2007275634B2/en not_active Ceased
- 2007-07-20 CN CN200780035017.9A patent/CN101516335B/zh not_active Expired - Fee Related
- 2007-07-20 ES ES07810647T patent/ES2340631T3/es active Active
- 2007-07-20 MX MX2009000770A patent/MX2009000770A/es active IP Right Grant
- 2007-07-20 BR BRPI0715423-2A patent/BRPI0715423A2/pt not_active IP Right Cessation
- 2007-07-20 US US12/374,383 patent/US8455662B2/en not_active Expired - Fee Related
-
2010
- 2010-05-14 CY CY20101100427T patent/CY1110037T1/el unknown
- 2010-05-25 HR HR20100293T patent/HRP20100293T1/hr unknown
-
2012
- 2012-02-28 RU RU2012107218/15A patent/RU2012107218A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2046292A2 (en) | 2009-04-15 |
AU2007275634A1 (en) | 2008-01-24 |
WO2008011154A2 (en) | 2008-01-24 |
RU2009105819A (ru) | 2010-08-27 |
PL2046292T3 (pl) | 2010-08-31 |
DE602007005139D1 (de) | 2010-04-15 |
BRPI0715423A2 (pt) | 2013-07-02 |
US20100040677A1 (en) | 2010-02-18 |
PT2046292E (pt) | 2010-04-26 |
RU2012107218A (ru) | 2013-09-10 |
US8455662B2 (en) | 2013-06-04 |
JP2009544617A (ja) | 2009-12-17 |
CN101516335B (zh) | 2014-01-08 |
AU2007275634B2 (en) | 2011-01-20 |
DK2046292T3 (da) | 2010-06-07 |
SI2046292T1 (sl) | 2010-06-30 |
MX2009000770A (es) | 2009-01-28 |
EP2046292B1 (en) | 2010-03-03 |
WO2008011154A3 (en) | 2008-06-26 |
CA2657346A1 (en) | 2008-01-24 |
HRP20100293T1 (hr) | 2010-06-30 |
ES2340631T3 (es) | 2010-06-07 |
CN101516335A (zh) | 2009-08-26 |
ATE459338T1 (de) | 2010-03-15 |
RU2452469C2 (ru) | 2012-06-10 |
KR20090033904A (ko) | 2009-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110037T1 (el) | Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες | |
WO2007027941A3 (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
EA200870545A1 (ru) | Новые гетероциклические соединения | |
WO2006035417A3 (en) | Dihydropyrimidine microcapsule - formulations | |
MX2009008540A (es) | Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina. | |
WO2009032034A3 (en) | Stabilized picoplatin dosage form | |
WO2007008752A3 (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
WO2010015567A3 (en) | Controlled release formulations using intelligent polymers | |
WO2005112633A3 (en) | Compounds and compositions for delivering active agents | |
TW200716202A (en) | Pediatric formulation of topiramate | |
UY29701A1 (es) | Formulaciones líquidas para la administración controlada de derivados de bencisoxazol | |
ECSP10010184A (es) | Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea | |
NO20090346L (no) | Pyrazolderivater som inhibitorer av cytokrom P450 | |
UA89315C2 (en) | Butylbenzene phthalein intravenous emulsion | |
WO2008006795A3 (en) | Indole compounds | |
MX2008001560A (es) | Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
WO2006094799A3 (en) | Pyridinone derivatives against malaria | |
CR20220014A (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos | |
WO2007124700A3 (en) | Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof | |
WO2010080414A3 (en) | Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents | |
PA8646301A1 (es) | Inhibidores de la adenilato ciclasa soluble | |
WO2008004100A3 (en) | Therapeutic compounds | |
WO2008015530A3 (en) | Stable solid oral formulation of pantoprazole | |
WO2015164581A8 (en) | Pharmaceutical formulation of an anti-guanylyl cyclase c antibody conjugate comprising histidine or a salt thereof and polysorbate 20 | |
WO2006111853A3 (en) | Stable solid dosage forms of acid labile drug |